RNA Interference and Cancer Therapy. RNA Interference and Cancer Therapy. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment. Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3′ untranslated region. + Author Affiliations *To whom correspondence should be addressed.
Tel: +81 29 861 9464; Fax: +81 29 861 2900; Email: renu-wadhwa@aist.go.jp Correspondence may also be addressed to Chae-Ok Yun. Tel: +82 2 2228 8040; Fax: +82 2 2227 7751; Email: chaeok@yuhs.ac Received December 27, 2010. Revision received April 30, 2011. Accepted May 27, 2011. MicroRNAs (miRNAs) are a class of noncoding small RNAs that act as negative regulators of gene expression. To identify miRNAs that may regulate human cell immortalization and carcinogenesis, we performed comparative miRNA array profiling of human normal and SV40-T antigen immortalized cells. Journal of Experimental & Clinical Cancer Research | Abstract | Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro. FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines. FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines - Life Sciences Social Network.
Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells - Life Sciences Social Network. Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients - Life Sciences Social Network. Breast Cancer Research | Abstract | Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Seq faces a tough road to the cancer clinic.
Despite the development of molecular classifications, and prognostic and predictive gene-expression signatures, microarray-based studies have not yielded definitive answers to many of the questions that remain germane for the successful implementation of personalized medicine. Similar challenges are likely to be encountered in translating next-generation sequencing data into clinically useful information. Needs Challenges Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS. Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol [Epub ahead of print]. Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway - Life Sciences Social Network. Dicer and miRNA in relation to clinicopathological variables in colorectal cancer patients - Life Sciences Social Network.
BioPortfolio Cancer: BioPortfolio News Dicer an... BioPortfolio Cancer: BioPortfolio News Overexpr... Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy - Life Sciences Social Network. Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. MiRNA-223 Promotes Gastric Cancer Invasion and Metastasis by Targeting Tumor Suppressor EPB41L3 - Life Sciences Social Network. Direct visualization at the single-cell level of siRNA electrotransfer into cancer cells. Access : Developing therapeutic microRNAs for cancer : Gene Therapy. UofL research shows removal of a tiny RNA molecule can inhibit cancer growth - Life Sciences Social Network. PDGF induced microRNA alterations in cancer cells - Life Sciences Social Network.
PiRNA, the new non-coding RNA, is aberrantly expressed in human cancer cells - Life Sciences Social Network. Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity. RNA analysis raises hopes of early cancer diagnosis. Molecular Cancer | Abstract | Expression patterns of microRNAs associated with CML phases and their disease related targets. SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer.